No. 11: Abbott (medical device segment)
Abbott Park, Ill.
2018 revenues: $11,400,000,000
Fiscal year ending: Dec. 31, 2018
Last year’s rank: 14
Miles White, chairman & CEO; Robert Ford, president & COO; Hubert Allen, EVP, GC & secretary; John Capek, EVP, ventures; Lisa Earnhardt, EVP, medical devices; John Ginascol, EVP, core diagnostics; Andrew Lane, EVP, established pharmaceuticals; Mary Moreland, EVP, HR; Daniel Salvadori, EVP, nutritional products; Andrea Wainer, EVP, rapid & molecular diagnostics; Brian Yoor, EVP, finance & CFO; Roger Bird, SVP, U.S. nutrition; Chuck Brynelsen, SVP, Abbott Vascular; Jaime Contreras, SVP, core laboratory diagnostics, commercial operations; Robert Funck, SVP, finance & controller; Sammy Karam, SVP, emerging markets established pharmaceuticals; Joseph Manning, SVP, international nutrition; Corlis Murray, SVP, quality assurance, regulatory & engineering services; Michael Pederson, SVP, cardiac arrhythmias & heart failure; Christopher Scoggins, SVP, rapid diagnostics; Jared Watkin, SVP, diabetes care; Alejandro Wellisch, SVP, established pharmaceuticals, Latin America; Randel Woodgrift, SVP, CRM
Abbott (NYSE:ABT) got behind the diabetes market in a big way this year, investing heavily in its FreeStyle Libre system, with CEO Miles White staking a claim on sensor-based CGMs as the future standard of care. White ignited speculation on a possible succession plan when he tapped Abbott veteran Robert Ford as president and COO — the first second-in-command at Abbott in more than a decade. The company added to its structural heart portolio by exercising the option on Cephea Valve Technologies and its transcatheter mitral valve device. Full-year profits surged 396.4% to $2.37 billion, on sales growth of 11.6% to $30.58 billion. – BP